Stats

Today changed: Sep11Oracle10Q original https://www.sec.gov/Archives/edgar/data/1341439/000119312526389274/orcl-20260831.htm accessibleviaEDGARCLI, first60kchars only. (1) Q1 OCF23.103bn includes11.363bnfinancingprepayments;capex28.499bn -> FCF-5.396bn. (2) NetATM equityissuance19.909bn fundsbuildout; exfinancingprepaymentFCF-16.759bn isanalyticalbridge, notGAAP. (3) Additional288bnleases expectedcommenceFY27Q2–FY29 for15–19years; notPVrecognizedliability. RPO664bn with13%=86.32bnexpectedrevenuewithin12months is not cash/profit andcannotoffsetleasesdollarfordollar. Strongestbear: longfixedcapacitycommitments plusdilution require utilizationandmarginstocatchup. Counter: customerprepaymentsandlargecontractedbacklogsharefundingrisk andcouldproducehighfuturecash. Threeorders: buildoutfunding -> equipment/powerpaymentsandfutureleaseobligations -> stockholdercashdependsonprofitableusagewithlessflexibility. Nonewrunupdate; noorder. CPRT Sep11 https://www.sec.gov/Archives/edgar/data/900075/000119312526388383/d138398dsctoc.htm ispreliminarytendercommunications, notcommencement/expiry. 1 plannedACVdeal ->2 regulator/integration/cashcommitment ->3 returnsoncapitalmustbeatcashalternative; counterdealerwholesaleplatformsynergies. No fixedarbitragedate fromSC TO-C. ADBE latest2filingsonlySep10/Sep8, no newSep11returned; priorcashanalysisreused, no organicgrowthbridgeverified. FullCPRTexhibittranscript andOraclelater10Qsections are explicitgaps, not presumedunchanged.

Bounded cross-market screen reaches US retail/publishing/restaurants/software, overseasNEXT/Egetis, FDA panels and macro; not an exhaustive globalcensus. Dates verified in observations25297–25304. NKEOct1approx16:15ET earnings -> defaultSep30exit; NXT.LSep17dateonly existing34; EGTX.STSep28dateonlyPDUFA, cash378MSEKasJun30 includesApr350MSEKgrossfinancing, conditionalPRV notcash. FDXexternalSep17estimate conflicts withunhelpfulissuerhomepage; no primaryconfirmation, no actabledate. Sep9FederalRegister https://www.govinfo.gov/content/pkg/FR-2026-09-09/pdf/2026-18349.pdf setsOct1 09–13ET strainselectionmeeting, NOTSep24(commentdeadline) ornameddrugapproval; no companypayoffidentified, rejectentry. USMondaySep14HAINBMO/HITIandPLAYAMC remainverified; defaultlastsessionexitSep11haspassed. Prior HITI244/HAIN382/PLAY848 failedoruncertain anddifferententrywindows; no latebuy. Sources https://investors.nike.com/investors/news-events-and-reports/investor-news/investor-news-details/2026/NIKE-Inc--Announces-First-Quarter-Fiscal-2027-Earnings-and-Conference-Call/default.aspx ; https://www.nextplc.co.uk/investors/reports-and-presentations/2026-27 ; https://attachment.news.eu.nasdaq.com/aa8bae6e3da62b95404c23eb6ec2cc25a ; https://investors.fedex.com/ ; MondayissuerURLs25302–04. Crypto macrodates alone do not identify thisfund's datedcompanyrunup; no tokenevent or tradablepricededge established. Premises: calendarverification is necessary butinsufficient; eligibility/FX/payoffuncertainforforeignnames; passedwindows cannotbemoved. Conclusion zeroallocation, preserveoutcomemonitors/collectors. No separatebook proposed because no independently demonstrated outside-mandateoperation.

Executed required CLI: node /app/agent/dist/backtest.js --symbols SCHL --strategy momentum --lookback20 --days1095 --stop-pct5 --target-pct15. 752bars,50trades, return-20.343012%,maxDD46.486672%,win30%,meantrade-.284097%,buyhold-16.387760%. Source https://runway.adityaperswal.workers.dev/data/stock-bars . This CLI result is a gross/default-feed diagnostic without its own reserved holdout or verified15min fills, so cannotauthorizecapital. Separate event study2768 uses explicitIEX, fees/slippage and fixed2021–24training versus2025–26knownholdout. Premises: dateconfirmedSep24 does notmakeany technicalrulevalid; CLInegative; eventstudytrainingalsonegative. Conclusion no momentum-basedentry. No parameterwinnerselected to rescue the result.

Numpyseed91200;100000 IID paths of10 trades resampled from16 SCHL trainingevent returns ofthe preregisteredT5/1ADRstop/3ADRtarget dailyproxy. Same underlying22issuerdatecohort andexplicitIEXsource https://runway.adityaperswal.workers.dev/data/stock-bars?feed=iex&adjustment=all . Quarterfunddeploymentmeanterminal-.258428%,lossfrequency55.485%,p05/p95[-4.54516,+4.46660]%,95thpercentileDD5.10136%. Fullfundmean-1.14268%,lossfrequency57.209%,p05/p95[-17.35808,+18.26072]%,95thDD19.18431%. These are model frequenciesconditionalon16events, not estimates from100000independentobservations, and omitunseenFDAgaps/regimechanges. Premises: historicaltrainingedge negative; repeatedtrades compoundthatloss; sizingonlychangesamplitude. Conclusion allocation0, traininghalfKelly0; cannot manufacturepositiveexpectancybyquarterprobe. Strongcountercase unseennewregimecouldimprovepayoff, but needsprospectiveevidence, not shortfall349.01. Hardlimit: fund49.14; anassumed50%wholefundgap costs24.57=2.88723%account, totalloss5.77445%; these deterministicstresslosses carry no assignedodds. No traded simulation andno live stop.

Frozen before new returns in note2456: T-5open to T-1close, stop1 prior20ADR, target3ADR, static daily proxy.22 issuer release dates https://investor.scholastic.com/financial-information/quarterly-results verified, train2021–24N16, knownholdout2025–Jul2026N6. ExplicitIEX adjusted1429bars https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=SCHL&timeframe=1Day&feed=iex&adjustment=all . Python custom entry-day/gap-open stop-first barrier fills with targets capped; vectorbt longonly from_orders, fees5bp/slip10bp eachside, initialcash100. Reconciled count and compounded returns exactly. Two marks/session drawdown includes entryfees but missesintradaytrough; no15min/+2Rtrailing or dividendcash execution validated. Training return-2.64033%,DD12.96266%,win37.5%,mean-.107976%,W4.11688%,L2.64289%,5targets. Knownholdout+2.15046%,DD7.22507%,win66.667%,mean+.407757%,W2.16255%,L3.10184%,ZEROtargets. Bootstrap20k95%meanCI[-2.03654,3.12124]%. Stress25bpslip givestrain-7.20323%,holdout+.328197%,win50%,CI[-2.32999,2.81234]%. T3/T10 sweep training negative underbothcosts, holdoutsalso negative; no bestvariantadoption. Gross3R geometry is less than3R net and empiricalwins aretimeexits, notdemonstratedtailcapture. HalfKelly capitalformula .5*(pW-(1-p)L)/(WL) yields0 intraining; mechanicallycapped1 inselectedknownholdout is unstable andNOTadopted. Prior763 hadseen sameholdout; this is a changedexit robustness experiment, not fresh independentOOS. Historicaldateannouncementavailability/earlynews and corporateactionexecution remain gaps. Conclusion noentry; preserveSep17paperwindow, notMondayearlierentry. Scripts research/test_schl.py, manifestobservations andtradeoutcomes25287 saved.

September11 explicit IEX daily prices, source https://runway.adityaperswal.workers.dev/data/stock-bars?timeframe=1Day&feed=iex&adjustment=all . SCHL34.975 belowSMA20 38.65/SMA50 41.671; RSI14 25.867;20sessionreturn-15.376%;ADR20 .89175. Hypothetical1ADRstop34.08325/3ADRtarget37.65025 has gross3R, less than3R after costs; it is a diagnostic price geometry, not a justified order. HOFT12.525,20day-15.600%, firstIEXopen+7.239% butclose-.358% supports skepticism about headlineprofit; sparse IEX volume1952.5/day cannot certifyliquidity. KR closed58.46,+2.6334% despiteguidancecut, so bearishsalesheadline alone missedcashresilience. SRRK55.39 dailyclose precedesapproval22:25UTC; no measuredpostapprovalreaction. SPY764.14,+.8273% despiteweakerconsumercontext; no causal attribution. Premises:1 event/timestamp alignment matters;2 oversold insidefallingtrend is not reversalproof;3 stop/target geometry is not expected payoff. Conclusion remainflat pendingindependentwindowvalidation; no existing stopstotighten. Strongcountercase oversoldrally is possible, testedwithoutchangingentrywindow. Equity/staleprice49.14affordsoneSCHLshare (~71.17%fund), noSRRKwhole share; no fractionalovernightrisk assumed safe.

Start state: $49.14 cash, no live lots or pending orders. Source runway:query_trades?fund=catalyst. Python recomputation of3 closed lots yields -$31.937258, win rate0%, mean return-16.380601%. RARE lost45.8601% or6.44035 times its intended stop risk; IONS and MIRM were operator liquidations, so their returns do not estimate natural strategy outcomes. Planned target/risk ratios were1.71739,1.40385,1.082 respectively, all below current3R mandate. Premises: (1) three losses provide no observed average win; (2) two censored exits distort expectancy; (3) one stop gap dominates dollar losses. Conclusion: no calibrated positive half-Kelly from this record; approved allocation0 until a separate valid setup passes. This is not proof every FDA run-up has negative expectancy. Countercase: early favorable approvals can produce upside, as today's SRRK announcement shows; that argues for modeling both tails and earlier news, not assuming the scheduled date bounds risk. All three historical lots were fractional, limiting off-hours exits. Entry arrival quotes and timestamps are unavailable, so do not call stop shortfall execution slippage. Current whole fund total loss would be5.77445% of account; a hypothetical50%gap loses2.88723%, independent of monthly revenue need.

Premises: (1) September11 BLS August CPI +0.4% MoM, core +0.3%; core YoY slowed to2.4%. (2) Real hourly pay -0.1% MoM, while longer hours lifted real weekly pay0.2%. (3) Michigan preliminary sentiment47.8 from51.7, one-year inflation expectations4.6% from4.0%. (4) Census applications531728 fell7.8%, projected next-four-quarter formations28501 fell4.6%; these are not actual August startups. Conclusion: demand-sensitive HOFT/SCHL/KR deserve scrutiny of volumes, margins and cash; these releases do not supply a dated company run-up edge. Strongest countercase: KR kept EPS5.10–5.30 and FCF2.7–2.9bn guidance despite1pp sales-midpoint cut; accounting/pharmacy headwinds differ from unit demand, and weekly purchasing power improved. Facts from agency surveys/admin records have different populations and collection lags. No prior forecast was registered, no measured surprise or causal claim about today's tape. Sources https://www.bls.gov/news.release/cpi.nr0.htm ; https://www.bls.gov/news.release/realer.nr0.htm ; https://www.sca.isr.umich.edu/ ; https://www.census.gov/econ/bfs/current/index.html ; https://www.thekrogerco.com/ir-feed-item/kroger-reports-second-quarter-2026-results-and-updates-guidance-for-2026/ .

No open theses/lots in venue ledger; no invented stop resets. SRRK:1 approval permits treatment andlaunch;2 payercoverage, infusioncapacity and safety determine paidstarts;3 recurringcash versuslaunchspend determines dilution/valuation, while backgroundSMN2therapyprovidersmaybenefit fromcomplementaryuse. Bearaccessfrictions/fractures; counter broadlabel/PRV. TLX:1 unknownSep11decisioncouldapprove/reject;2 launchcashoradditionalCMC/clinicalspend follows;3 otherpipelinefunding andradiopharmacyutilizationamplifyequityimpact. Do not claim FDA silence provesdelay. HOFT:1 refundsboostliquidity;2 finite recoveriesfade whilebacklogmustbecomeprofitable shipments;3 enduringweakdemandcouldforcecashconservation/lesscapitalreturns. Counter costcuts/no bankdebt improve survival. KR:1 salesgrowthguidefalls1ppmidpoint;2 mix, priceinvestment, laborproductivity and pharmacyheadwinds interact;3 unchangedFCF/EPSdepends onmargins, withbuybacksreducingfloat butconsumingcash. Counter profitguidanceunchanged; salescutnotfullvolumeproxy. SCHL:1 saleleasebackconvertsassetstocash;2 leasesbecomefutureoperatingobligations;3 recurringcash/bookfairs mustcoverrent, contentinvestment andcapitalreturns. Counter35–40mFY27FCFforecast and lowerfloat mayrewardowners. These are conditionalchains, not assignedprobabilities. Sources: SRRKoriginalin25168; https://telixpharma.com/news-views/fda-accepts-nda-for-tlx101-px-pixclara/ ; https://investors.hookerfurnishings.com/news-releases/news-release-details/hooker-furnishings-reports-profitable-quarter-and-first-half ; https://www.thekrogerco.com/ir-feed-item/kroger-reports-second-quarter-2026-results-and-updates-guidance-for-2026/ ; https://investor.scholastic.com/news-releases/news-release-details/scholastic-reports-fourth-quarter-and-fiscal-2026-results .

No holdings, so these are watchlist challenges, not exit instructions. SRRK primary https://scholarrock.gcs-web.com/news-releases/news-release-details/scholar-rock-announces-fda-approval-isembyldtm-apitegromab-mstn (Sep11 18:25EDT RSS) reports ISEMBYLD approval19days beforeSep30goal. Premises:1 regulatory risk for this US indication is resolved;2 eligible patients must already receiveSMN2-targeted therapy and shipping/payeraccess are prospective;3 voucher award is not cash sale. Bear: launch conversion, fractures9%vs2%, infusion logistics and manufacturing still constrain cash; approval has already arrived so cannot buy aSep30run-up. Countercase broad age>=2label, firstmuscle-targeted treatment and voucher can support repricing, but no independent net postapproval strategy established. HOFT Sep11original https://investors.hookerfurnishings.com/news-releases/news-release-details/hooker-furnishings-reports-profitable-quarter-and-first-half :1 Q2OI1.3m contains~3.8mnetoperating tariffbenefit (4.3COGS-.5customercredits);2 simple normalizedOI~-2.5m;3 revenue-8.7%and noadditionalmaterialtariffrecoveries expected. Bear: headline profits overstate recurring demand and cashrelease cannot recur. Countercase cash18.7m/no bankdebt, backlog+6.2%YoY and lasting17.5m annualcostcuts may support recovery; July improved exrefund permanagement, not independently quantified. H1FCF24-1.1=22.9m, subtract7.9refund=>15m before other workingcapital; not perpetual cash. Valid conclusion reject automatic entries; financial soundness limited by rounded accounting bridges and issuer bias, no market valuation model yet.

Final list_jobs returned actual08:15:37UTC executions for223/224, exit0, final END and7/11panel receipts. This supersedes2734's pending server verification; local success was subsequently corroborated by venue output. All five original source-collection workflows remain active through126/132/172/223/224, with no trading instructions. Compact previews establish completion/error visibility, not full document retention or economic truth. Next runs22310:15UTC and22416:15UTC; nextmanager12:30UTC. Source runway:list_jobs?fund=catalyst ; actual receipt observations recorded this run.

Start49.14 fund cash/850.99 account; no holdings or pending orders. Goal is a dated run-up with exit before first news; binding constraint is an eligible executable payoff, not349.01 monthly shortfall. Premises:1 immediate FDA/call events leave no ordinary prior-session entry; Monday HITI/HAIN/PLAY tested T3/T10/T4 windows already passed.2 Frozen event studies2730 remain inconclusive or rejected; no new last-day3R rule was validated.3 Fresh range stress2724 is negative after assumedcosts and explicitly cannot calibrate FDA gaps.4 Overnight primary results2712–2715 change fundamental context but are past earnings, not new run-up entries. Conclusion: approved notional0, no stops/targets/orders placed, preserve49.14cash. Validity follows unmet timing/payoff gates; soundness limited to reviewed candidates, short pricehistory, retrospective selected studies and named calendar/access gaps. Strongest countercase is HITI positive trend and cash-driven reratings; a potential rally cannot validate buying outside the tested window. Half-Kelly is not estimated from uncalibrated intraday/FDA odds; approved allocation0. New measured edge with a future verified date would change this decision; pressure to recover losses will not. Monitors278–280 and jobs223/224 preserve follow-up. No distinct proven operation justifies a FUND line. Sources: issuer dates in2733/observations25034–25040; https://runway.adityaperswal.workers.dev/data/stock-bars ; https://investor.oracle.com/files/content_files/1q27-pressrelease-September_FINAL.pdf ; https://www.sec.gov/Archives/edgar/data/1318008/000117184326005980/exh_991.htm .

1. list_jobs and saved notes confirm126/132/172 have final END markers. Old205/209 exit0 outputs truncate before completion, so exit code alone is insufficient. 2. Preserved original source scripts, wrapped every print in bounded panel receipts with length/hash/preview/error summaries. Local plain and final losslessly packed variants executed successfully:7 print panels for205,11 for209; both actual END observed, output<2200characters. 3. Initial scheduling failed4000-character schema; compressed2845/3049character variants preserve identical decoded logic. Originals cancelled, replacements submitted on same120/480minute cadence and45/62remaining runs. Full raw content exists only inside each sandbox; saved receipts deliberately use previews and never substitute for reading originals. Conclusion: collection completion is auditable; server first-run output remains to be checked at next run. Preserve source/branch manifests in list_jobs cancelled205/209 and note2305; no sixth collector, no economic conclusion from hashes. Sources runway:list_jobs?fund=catalyst ; runway:query_research?fund=catalyst&kind=notes ; scripts pre91108/collector205.sh and collector209.sh.

Start49.14 fund cash, no holdings/orders. FridaySep11: KR08ET call, HOFT09ET call; neither gives exact first-news minute. TLX Pixclara PDUFA date only, early news possible. CPI/real earnings08:30ET, Michigan preliminary sentiment and Census formations10ET, Fed Z1noonET. MondaySep14: HAIN before-open, HITI/PLAY after-close; default prior-session exit is today. Smaregi4431.T issuer dateSep14, hour/venue/FX unverified. BLS/Census show noMonday entries, but Fed has routine CP13ET/H10/H15 16:15ET; do not claim no macro. FDA general calendar rendered without rows, so exhaustive coverage is unproven. Existing broad census2412 is reused context, not a new full-market screen. Strong cash/clinical evidence changes research priority; weak or missing releases retain cash or date uncertainty. Neither outcome bypasses independent net edge and pre-event exit. Crypto macro exposure alone does not supply this mandate's dated-company run-up. Sources recorded25034–25040/25080–25083/25130: https://www.bls.gov/schedule/2026/09_sched.htm ; https://www.sca.isr.umich.edu/ ; https://www.census.gov/economic-indicators/calendar-listview.html ; https://www.federalreserve.gov/newsevents/2026-september.htm ; issuer URLs in those observations and monitors13/193/278/280. No orders/stops required while flat; next manager12:30UTC.

Facts are recorded2712–2715,25034 with original URLs. Conditional chains: (1) Oracle prepayments finance capacity; (2) delivery consumes equipment/power and creates service obligations; (3) shareholder returns depend on utilization and margins after financing, while hardware/power suppliers may receive cash earlier. Countercase: contracted customer funding can reduce equity dilution. Adobe: (1) AI adoption attracts users; (2) paid conversion and inference costs determine margin; (3) durable cash can fund buybacks, but free users alone cannot. Copart: (1) ACV purchase uses cash; (2) integration/HSR affect timing and synergies; (3) per-share value depends on returns above alternative cash deployment. Zumiez: (1) soft traffic pressures sales; (2) fixed leases and buybacks consume liquidity; (3) weak holiday cash could reduce future capital returns. TLX: (1) approval/CRL changes access; (2) launch cash or continued costs follow; (3) funding and other pipeline valuations amplify equity gaps. These are scenarios, not probability estimates or recommendations to trade counterparties. Reconsider only with incremental primary cash evidence plus independent executable event edge. Sources https://investor.oracle.com/files/content_files/1q27-pressrelease-September_FINAL.pdf ; https://www.adobe.com/cc-shared/assets/investor-relations/pdfs/01906202/au56y4ter.pdf ; https://www.sec.gov/Archives/edgar/data/900075/000119312526388064/d138322dex991.htm ; https://www.sec.gov/Archives/edgar/data/1318008/000117184326005980/exh_991.htm ; https://telixpharma.com/news-views/fda-accepts-nda-for-tlx101-px-pixclara/ .

Read originals244,382,848; no rerun, pooled sample or holdout selection. HITI fixed T-3/T-1 vectorbt: training2022–23 N8 +31.7294%, holdout2024–Jun26 N11 +3.75545%, DD8.65185%, win63.6364%; stress+.38739%, meanCI[-.73259,1.53296]%, no validated current3R/15-minute exit. HAIN T-10/T-1: trainN13 +39.3858%, holdoutN6 -54.89695%, DD56.6170%, win16.6667%. PLAY T-4/ATR exits: trainN16 -13.155%, holdoutN6 +6.87897%, DD12.73711%, win66.6667%, meanCI[-4.485,7.251]%. Prior CLI controls280/393/848 also reviewed; generic momentum is not event validation. All studies include assumed fees/slippage and chronological splits; reviewed holdouts are now known, not untouched forward evidence. Conclusion: preserve rejected or inconclusive rules. All tested entry windows passed before today's final pre-event session; a new intraday purchase would require a new independent test. Sources https://runway.adityaperswal.workers.dev/data/stock-bars ; https://ir.hain.com/financial-information/quarterly-results ; https://hightideinc.com/high-tide-to-announce-third-fiscal-quarter-2026-financial-results/ ; https://daveandbusters.gcs-web.com/news-releases/news-release-details/dave-busters-entertainment-inc-report-second-quarter-2026 .

1. Direct query_trades fund=catalyst again returns three closed entries and no holdings/orders. Prior exact ledger2679 remains unchanged: P&L-31.937258, win0/3, average winning return undefined; two operator exits censor intended holding periods. 2. RARE25.84entry/24stop/13.98976exit lost6.44035R. A stop is not a bound on loss. 3. The sample cannot estimate new-catalyst Kelly probabilities; lack of winning trades does not prove true win probability zero. Conclusion: no pooled odds or spurious order-type slippage calculation. Current gap-aware feasibility is fund49.14/account850.99; 50% fund-position gap2.8872% of account. Countercase: censored losses may understate prospective performance, but cannot validate an untested final-session entry. Source runway:query_trades?fund=catalyst ; prior measured figures2679, not a new sample.

1. Seed91108, numpy50000 resamples per name of71 complete daily H/L/C ratios to each day's open; translate to Sep10 reference price. Diagnostic1ADR stop/3ADR target, stop first if both, otherwise close; assumed30bp each side. 2. Mean net HITI-0.7844%,HAIN-0.9210%,PLAY-0.9050%,TLX-0.6544%; target frequencies0/0/1.378/0%. 3. This is unconditional range analysis, not a catalyst backtest, holdout or executable 15-minute model. Entry/overnight gaps omitted, so TLX result cannot estimate FDA loss odds. A separate ASSUMED50% gap on full49.14 costs24.57,2.8872% account equity; full loss5.7745%. Conclusion: model does not defend inventing a last-day3R trade. Approved allocation0; no Kelly odds inferred from this uncalibrated simulation. More Monte Carlo paths do not enlarge71 empirical observations. Source https://runway.adityaperswal.workers.dev/data/stock-bars?timeframe=1Day&feed=sip&adjustment=all ; recorded vectors25095–25098 and pre91108/study.py.

1. Across nine selected symbols, momentum20 and SMA20 distance correlate0.5921. They share price inputs and are not two independent confirmations. 2. Seventy completed daily returns yield HITI/HAIN0.1290,HITI/PLAY-0.0343,HITI/TLX0.1465; remaining pair correlations range-0.0413 to0.0962. 3. This short selected sample misses rare joint gaps and current CPI exposure. Conclusion: low ordinary correlation cannot justify filling the fund with unvalidated earnings/FDA positions. No new regime filter selected. Countercase: diverse business drivers may diversify normal returns; require longer event-conditioned covariance and standalone positive net edges before sizing a basket. Source https://runway.adityaperswal.workers.dev/data/stock-bars?timeframe=1Day&feed=sip&adjustment=all ; vector observations25085–25099.

1. June1–September10 SIP adjusted daily history has71 bars per symbol; Sep10 close is a historical reference, not a live quote. HITI2.56>SMA20 2.4905>SMA50 2.3204, momentum20 +9.871%; PLAY8.17 is below9.4625/10.0246 and down21.215%. HAIN0.6395<SMA20 0.6925, dollar ADV only474144. 2. HITI1ADR0.07847 gives diagnostic stop2.48153/3R target2.79541, above20-day high2.70; no demonstrated last-day invalidation/target exists. 3. TLX11.90>SMA20 11.70425 cannot neutralize date-only FDA risk today. SPY below both20/50 averages is context, not a fitted filter. Conclusion: no new last-session rule; no queued order. HITI T-3, HAIN T-10 and PLAY T-4 entry dates passed. Whole-share affordability19/76/6/4 respectively is feasibility only. Source https://runway.adityaperswal.workers.dev/data/stock-bars?timeframe=1Day&feed=sip&adjustment=all ; issuer dates observations25034–25040.

1. Q2 comps fell2.1%; the37 days throughSeptember7 fell3.5%, so earlyQ3 does not show demand recovery. 2. Six-month OCF-27.276m less4.880m capex gives-32.156m FCF; cash buybacks28.972m raise combined drain to61.128m, versus63.359m fall in cash plus securities sinceJanuary31. 3. Inventory is approximately flat YoY, reducing evidence for a large inventory buildup. Conclusion: no cash-backed recovery signal. The issuer's positive35.7m OCF narrative refers to the year-over-year cash bridge, not the negative six-month table; different periods reconcile both. Strong countercase is seasonally strong holiday cash and international growth; require paid cash and US traffic recovery rather than assume annualized H1 burn. Earnings completed, no new run-up entry. Source https://www.sec.gov/Archives/edgar/data/1318008/000117184326005980/exh_991.htm .

1. SEC Q4 results show gross margin41.7765% versus45.3044%, a3.5278pp contraction despite2.4% revenue growth. 2. FY OCF1604.492m less capex337.363m gives1267.129m FCF; lower investment explains improvement over prior1230.760m despite lower OCF. 3. ACV's approximately1900m equity price is1.4995x FY FCF; $10.50 cash tender remains subject to majority acceptance and HSR, with no financing condition. Conclusion: acquiree platform benefits may help future growth, but they do not reverse current margin pressure. Issuer forecasts EPS accretion only FY2028 onward. Exact tender commencement/expiry unconfirmed; no invented merger deadline or arbitrage order. This recovers earlier results/agreement gaps; operating unit detail and full Q&A remain gaps. Sources https://www.sec.gov/Archives/edgar/data/900075/000119312526387902/cprt-ex99_1.htm ; https://www.sec.gov/Archives/edgar/data/900075/000119312526388064/d138322d8k.htm ; https://www.sec.gov/Archives/edgar/data/900075/000119312526388064/d138322dex991.htm .

1. Q3 OCF $2.523bn less $85m capex gives $2.438bn FCF, covering $2.232bn cash buybacks 1.0923x. 2. GAAP EPS4.62 versus adjusted6.13 differs by1.51; stock/deferred compensation accounts for1.38 of that bridge. 3. Q4 revenue midpoint6.825bn is only0.962% above rounded Q3 sales6.76bn. Conclusion: cash generation supports the business, but acquisition-inclusive growth and product adoption percentages do not isolate organic AI monetization. Countercase: Firefly and enterprise adoption can compound into paid expansion. Reconsider upon a complete organic revenue/ARR bridge and durable cash conversion; no run-up trade after released earnings. Exact table OCF2523 supersedes rounded2520 used in exploratory arithmetic. Sources https://www.adobe.com/cc-shared/assets/investor-relations/pdfs/01906202/au56y4ter.pdf ; https://www.adobe.com/cc-shared/assets/investor-relations/pdfs/01906202/c6yetrerew.pdf .

1. September 10 issuer statements report $23.103bn Q1 OCF and $28.499bn capex. 2. Financing-component customer prepayments supplied $11.363bn, or 49.184% of OCF. Subtracting them as a sensitivity leaves $11.740bn OCF, still 44.226% above prior Q1; subtracting capex then gives -$16.759bn. This is not a GAAP correction or a forecast of recurring cash. 3. Net ATM issuance supplied $19.909bn. Conclusion: delivery growth is real issuer-reported evidence, but backlog growth is not self-funded equity cash flow. Strong counterargument: customer financing aligns funding with contracted demand and reduces external financing needs. What changes the view: documented conversion to profitable services and less capital required per incremental paid revenue. No purchase: earnings already occurred; no new dated run-up. Sources https://investor.oracle.com/files/content_files/1q27-pressrelease-September_FINAL.pdf ; https://www.prnewswire.com/news-releases/oracle-announces-q1-results-driven-by-triple-digit-growth-in-cloud-infrastructure-revenues-302875728.html .

Start:49.14fundcash,850.99account, no holdings or queued orders. Goal: net dated run-up with exit before release. Binding constraint is executable expectancy, not349.01monthly shortfall. Premises: (1) September8issuer confirmsSeptember29AMC, default prior-session exitSeptember28. (2) PrimaryT5/1ADRstop/3ADRtarget training2586 -7.89871%N15, holdout2587 -26.57828%N7, stress2589 -28.60560%, zero holdout wins. All tested training variants have negative compounded returns; positiveT3holdout is not adopted after inspection. (3) Actual15-minuteRTH audit2662 -27.72355%,DD29.76090%, no+2Rtrigger; small minute/daily entry differences remain. (4) Training halfKelly2658=0. (5) Fundamental2659 requiresH2542.289m adjustedFCF to meet640mFYmidpoint; seasonal cash improvement is possible but unproven. Conclusion: no orders or exit changes; allocation0. Validity follows unmet entry gates; soundness is bounded by selected company, retrospective calendars, overlapping news, seven-event test and assumed costs. Strongest countercase: positive recentT3returns and cash-led rerating; preserve research without selecting a rule by its test. Cash is chosen for this reviewed setup's negative expectancy, not proof every catalyst lacks edge. Existing250/205 retain date follow-up and both branches; no duplicate monitor/job. Receipt completeness205/209 remains a named gap. No separate FUND case. Analyses, observations, code archive and three lessons recorded; finished around06:18, within43planned/45maximum minutes. Sources https://ir.concentrix.com/news/news-details/2026/Concentrix-Schedules-Release-of-Third-Quarter-2026-Financial-Results-and-Investor-Conference-Call/default.aspx ; https://runway.adityaperswal.workers.dev/data/stock-bars ; fundamental issuerURL in2659.